000950 重药控股
已收盘 07-23 15:00:00
资讯
新帖
简况
重药控股与翰森制药正式启动新丰翼项目战略合作
南方财经网 · 11:07
重药控股与翰森制药正式启动新丰翼项目战略合作
重药控股：主要从事医药流通、医药研发（MAH）、医疗器械生产并投资参与医药工业
证券之星 · 07-16
重药控股：主要从事医药流通、医药研发（MAH）、医疗器械生产并投资参与医药工业
股市必读：重药控股（000950）7月13日董秘有最新回复
证券之星 · 07-14
股市必读：重药控股（000950）7月13日董秘有最新回复
重药控股：以医药流通为核心业务
证券之星 · 07-13
重药控股：以医药流通为核心业务
重药控股完成1540.66万股回购股份注销手续
证券日报 · 07-12
重药控股完成1540.66万股回购股份注销手续
重药控股的合规与经营风险透视：军采违规频发与三百亿应收款压力
新浪证券 · 07-10
重药控股的合规与经营风险透视：军采违规频发与三百亿应收款压力
股市必读：重药控股（000950）7月2日董秘有最新回复
证券之星 · 07-03
股市必读：重药控股（000950）7月2日董秘有最新回复
重药控股（000950）披露回购股份进展及结果暨股份变动公告，7月1日股价上涨1.8%
证券之星 · 07-01
重药控股（000950）披露回购股份进展及结果暨股份变动公告，7月1日股价上涨1.8%
重药控股（000950）披露副总经理离任公告，6月24日股价下跌2.66%
证券之星 · 06-24
重药控股（000950）披露副总经理离任公告，6月24日股价下跌2.66%
重药控股：2026年6月29日将召开2026年第三次临时股东会
证券日报网 · 06-24
重药控股：2026年6月29日将召开2026年第三次临时股东会
重药控股（000950）披露关于回购股份进展的公告，6月1日股价上涨0.34%
证券之星 · 06-01
重药控股（000950）披露关于回购股份进展的公告，6月1日股价上涨0.34%
股市必读：重药控股（000950）5月28日董秘有最新回复
证券之星 · 05-29
股市必读：重药控股（000950）5月28日董秘有最新回复
重药控股最新公告：参股子公司签订许可协议
证券之星 · 05-28
重药控股最新公告：参股子公司签订许可协议
重药控股：公司推行的双职董事长制度，是公司为深化改革、优化治理、集约配置管理人才推出的试点制度
证券之星 · 05-28
重药控股：公司推行的双职董事长制度，是公司为深化改革、优化治理、集约配置管理人才推出的试点制度
重药控股（000950）披露参股子公司药品获注册批准公告，5月25日股价上涨0.16%
证券之星 · 05-25
重药控股（000950）披露参股子公司药品获注册批准公告，5月25日股价上涨0.16%
重药控股最新公告：参股子公司左氧氟沙星注射液获注册批准
证券之星 · 05-22
重药控股最新公告：参股子公司左氧氟沙星注射液获注册批准
营收增长靠“铺网点”，利润薄如纸，重药控股业绩增长背后的隐忧
微博财经-财道工作室 · 05-18
营收增长靠“铺网点”，利润薄如纸，重药控股业绩增长背后的隐忧
重药控股（000950）披露2025年年度股东会决议公告，5月15日股价下跌1.04%
证券之星 · 05-15
重药控股（000950）披露2025年年度股东会决议公告，5月15日股价下跌1.04%
异动快报：重药控股（000950）5月12日10点12分触及涨停板
证券之星 · 05-12
异动快报：重药控股（000950）5月12日10点12分触及涨停板
股市必读：重药控股（000950）5月7日披露最新机构调研信息
证券之星 · 05-08
股市必读：重药控股（000950）5月7日披露最新机构调研信息
加载更多
公司概况
公司名称：
重药控股股份有限公司
所属行业：
批发业
上市日期：
1999-09-16
主营业务：
重药控股股份有限公司的主营业务是医药商业、仓储物流、医药工业和研发等业务。公司的主要产品是药品、医疗器械、中药饮片、保健产品。
发行价格：
4.63
{"stockData":{"symbol":"000950","market":"SZ","secType":"STK","nameCN":"重药控股","latestPrice":5.34,"timestamp":1784790183000,"preClose":5.32,"halted":0,"volume":24291956,"delay":0,"changeRate":0.0038,"floatShares":1713000000,"shares":1713000000,"eps":0.2524,"marketStatus":"已收盘","change":0.02,"latestTime":"07-23 15:00:00","open":5.29,"high":5.35,"low":5.23,"amount":129000000,"amplitude":0.0226,"askPrice":5.35,"askSize":6483,"bidPrice":5.34,"bidSize":605,"shortable":0,"etf":0,"ttmEps":0.2524,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":5,"adr":0,"adjPreClose":5.32,"symbolType":"stock","openAndCloseTimeList":[[1784770200000,1784777400000],[1784782800000,1784790000000]],"highLimit":5.85,"lowLimit":4.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1712778096,"isCdr":false,"pbRate":0.78,"roa":"--","peRate":21.156894,"roe":"1.47%","epsLYR":0.22,"committee":-0.405003,"marketValue":9146000000,"turnoverRate":0.0142,"status":0,"floatMarketCap":9146000000},"requestUrl":"/m/hq/s/000950","defaultTab":"news","newsList":[{"id":"2653184027","title":"重药控股与翰森制药正式启动新丰翼项目战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653184027","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653184027?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:07","pubTimestamp":1784776020,"startTime":"0","endTime":"0","summary":"南方财经7月23日电，据重药控股消息，7月22日，重药控股与翰森制药集团有限公司召开新丰翼项目签约会。根据协议，本次项目合作将覆盖重庆、河南、陕西、贵州、四川、甘肃、天津、宁夏、湖北9个省市。双方将整合自身优质资源，在市场准入、新兴业务等重点合作领域持续深化协同，打造产销一体化创新合作体系。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233818638391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","BK0250","BK1583","03692","000950","BK0071","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651411685","title":"重药控股：主要从事医药流通、医药研发（MAH）、医疗器械生产并投资参与医药工业","url":"https://stock-news.laohu8.com/highlight/detail?id=2651411685","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651411685?lang=zh_cn&edition=full","pubTime":"2026-07-16 15:03","pubTimestamp":1784185395,"startTime":"0","endTime":"0","summary":"证券之星消息，重药控股(000950)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，实验猴子价格越来越贵，会不会影响公司对创新药的研发？影响公司发展？重药控股回复：公司处于医药流通行业，主要从事医药流通、医药研发（MAH）、医疗器械生产并投资参与医药工业，其中医药流通为核心业务；医药研发主要以药品上市许可持有人的方式开展，目前以高端仿制药和特色现代中药为主。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600019000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000950","09939","BK1100","BK1583","BK1515","159938","09996","159883","BK1161","BK0250","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651753146","title":"股市必读：重药控股（000950）7月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651753146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651753146?lang=zh_cn&edition=full","pubTime":"2026-07-14 02:19","pubTimestamp":1783966749,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，重药控股报收于5.29元，上涨2.12%，换手率2.6%，成交量44.48万手，成交额2.36亿元。董秘最新回复投资者： 尊敬的董秘。交易信息汇总资金流向7月13日主力资金净流出165.05万元，占总成交额0.0%；游资资金净流出20.87万元；散户资金净流入185.92万元，占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400001669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0071","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119431","title":"重药控股：以医药流通为核心业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651119431?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:03","pubTimestamp":1783929797,"startTime":"0","endTime":"0","summary":"证券之星消息，重药控股(000950)07月13日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘。贵公司有什么科技业务没？也可以收购些半导体芯片行业的做下转型升级的。重药控股回复：公司处于医药流通行业，主要从事医药流通、医药研发（MAH）、医疗器械生产并投资参与医药工业，其中以医药流通为核心业务。感谢您的关注与建议！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300022098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0250","BK1161","09939","BK1515","BK1574","159938","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650163244","title":"重药控股完成1540.66万股回购股份注销手续","url":"https://stock-news.laohu8.com/highlight/detail?id=2650163244","media":"证券日报 ","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650163244?lang=zh_cn&edition=full","pubTime":"2026-07-12 19:09","pubTimestamp":1783854540,"startTime":"0","endTime":"0","summary":"重药控股股份有限公司发布公告称，公司已完成1540.66万股回购股份注销手续。 本次注销股份占注销前总股本的0.8915%，注销完成后，公司总股本由17.28亿股缩减至17.13亿股。重药控股表示，本次股份注销不会对公司经营、财务及债务履约能力产生重大影响，公司控制权未发生变化，仍符合上市条件。后续公司将办理注册资本变更、章程修订及工商变更登记等相关手续。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-12/doc-inihpymv7813129.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-12/doc-inihpymv7813129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000950","BK0250","BK0071"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650902665","title":"重药控股的合规与经营风险透视：军采违规频发与三百亿应收款压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2650902665","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650902665?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:17","pubTimestamp":1783664220,"startTime":"0","endTime":"0","summary":" 从区域龙头到央企子公司，重药控股在完成股权层面跨越的同时，其合规管理与经营质量正面临持续检验。近日，军队采购网公示信息显示，重药控股全资子公司重庆医药集团四川医药有限公司因“围标串标”被暂停全军采购资格。股权变更并未自动带来治理能力的同步提升，合规漏洞与经营压力仍是其面临的现实课题。 2024年以来，重药控股旗下至少7家子公司先后因军队采购违规被暂停资格，地域覆盖五个省级行政区。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-10/doc-inihhzsc8406567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","BK0071","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648687438","title":"股市必读：重药控股（000950）7月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648687438","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648687438?lang=zh_cn&edition=full","pubTime":"2026-07-03 02:44","pubTimestamp":1783017852,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，重药控股报收于5.17元，上涨1.37%，换手率1.82%，成交量31.43万手，成交额1.63亿元。公司公告汇总：重药控股股份回购已实施完毕，累计回购15,406,600股、支付8099.88万元，回购股份将全部注销以减少注册资本。本次回购已达到方案金额下限、未超上限，实施完毕；回购股份将全部注销，减少注册资本；相关主体在回购期间无买卖公司股票行为。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300002039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0071","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648541676","title":"重药控股（000950）披露回购股份进展及结果暨股份变动公告，7月1日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648541676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648541676?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:35","pubTimestamp":1782916514,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，重药控股报收于5.1元，较前一交易日上涨1.8%，最新总市值为88.14亿元。该股当日开盘4.99元，最高5.11元，最低4.93元，成交额达1.41亿元，换手率为1.62%。近日，重药控股披露《关于回购股份进展及结果暨股份变动的公告》。公告显示，公司于2025年7月审议通过回购股份方案，拟使用自有资金及专项贷款，以集中竞价方式回购公司股份，用于减少注册资本。回购股份将全部注销，减少注册资本。相关主体在回购期间无买卖公司股票行为。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0071","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645966819","title":"重药控股（000950）披露副总经理离任公告，6月24日股价下跌2.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645966819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645966819?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:22","pubTimestamp":1782310945,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘，重药控股报收于5.13元，较前一交易日下跌2.66%，最新总市值为88.66亿元。近日，重药控股股份有限公司披露《关于副总经理离任的公告》。公告显示，公司于2026年6月24日收到副总经理杨清华女士提交的辞职申请，因其工作调整，申请辞去副总经理职务，转任公司调研经理。杨清华女士原定任期至第九届董事会届满，其职务变动不影响公司正常运营。截至公告日，其未持有公司股份，无应履行未履行承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400043944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0250","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645129819","title":"重药控股：2026年6月29日将召开2026年第三次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2645129819","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645129819?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:01","pubTimestamp":1782309660,"startTime":"0","endTime":"0","summary":"证券日报网讯6月24日，重药控股发布公告称，公司将于2026年6月29日召开2026年第三次临时股东会。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-24/doc-iniepqxq6077899.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-24/doc-iniepqxq6077899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0071","000950","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895007","title":"重药控股（000950）披露关于回购股份进展的公告，6月1日股价上涨0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640895007?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:44","pubTimestamp":1780325060,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，重药控股报收于5.83元，较前一交易日上涨0.34%，最新总市值为100.75亿元。该股当日开盘5.85元，最高5.86元，最低5.72元，成交额达1.77亿元，换手率为1.77%。近日，重药控股发布《关于回购股份进展的公告》。公告显示，公司于2025年7月10日和7月28日分别召开董事会及临时股东会，审议通过回购公司股份的议案。回购进展符合相关法规及公司方案要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100041460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0071","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639660690","title":"股市必读：重药控股（000950）5月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2639660690","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639660690?lang=zh_cn&edition=full","pubTime":"2026-05-29 01:17","pubTimestamp":1779988630,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，重药控股报收于5.77元，下跌1.54%，换手率1.64%，成交量28.39万手，成交额1.64亿元。来自公司公告汇总：重药控股参股子公司药友制药获授纬利妥米单克隆抗体在中国境内及港澳台地区的独占开发与商业化权利。协议涉及首付款至多3亿元、上市里程碑至多2.5亿元、技转里程碑至多5000万元，并根据年度净销售额支付销售里程碑及提成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900001582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","BK0250","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638662780","title":"重药控股最新公告：参股子公司签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2638662780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638662780?lang=zh_cn&edition=full","pubTime":"2026-05-28 18:39","pubTimestamp":1779964797,"startTime":"0","endTime":"0","summary":"重药控股(000950.SZ)公告称，公司参股子公司药友制药与智翔金泰签订许可协议，获授予GR1803注射液(纬利妥米单抗)在中国境内及港澳台地区临床开发、商业化的独占权利及生产工艺研究、生产的排他权利。药友制药将支付至多6亿元的首付款、上市里程碑及技转里程碑款项，并基于净销售额支付销售里程碑及销售提成。该产品目前处于新药上市申请审评阶段，但存在研发及商业化不确定性风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800036079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","000950","BK0071"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638668392","title":"重药控股：公司推行的双职董事长制度，是公司为深化改革、优化治理、集约配置管理人才推出的试点制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2638668392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638668392?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:15","pubTimestamp":1779952518,"startTime":"0","endTime":"0","summary":"证券之星消息，重药控股(000950)05月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司的双职董事长制度是一种什么的制度，麻烦介绍下重药控股回复：公司推行的双职董事长制度，是公司为深化改革、优化治理、集约配置管理人才推出的试点制度。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800021935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000950","BK0071","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638312855","title":"重药控股（000950）披露参股子公司药品获注册批准公告，5月25日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638312855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638312855?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:41","pubTimestamp":1779702090,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，重药控股报收于6.19元，较前一交易日上涨0.16%，最新总市值为106.97亿元。该股当日开盘6.15元，最高6.27元，最低6.08元，成交额达1.7亿元，换手率为1.6%。近日，重药控股股份有限公司披露《关于参股子公司药品获注册批准的公告》。该药品注册分类为化学药品3类，规格为20ml:0.5g，上市许可持有人为重庆药友制药有限责任公司，批准文号为国药准字H20264412。该事项将丰富参股子公司产品线，但后续销售存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500025156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","000950","BK0071"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637881315","title":"重药控股最新公告：参股子公司左氧氟沙星注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637881315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637881315?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:30","pubTimestamp":1779445856,"startTime":"0","endTime":"0","summary":"重药控股(000950.SZ)公告称，公司参股子公司重庆药友制药的左氧氟沙星注射液药品注册申请获国家药监局批准，用于多种敏感细菌感染。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200036848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000950","BK0071","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636021664","title":"营收增长靠“铺网点”，利润薄如纸，重药控股业绩增长背后的隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2636021664","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636021664?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:04","pubTimestamp":1779095040,"startTime":"0","endTime":"0","summary":"财报显示，2025年公司营业收入824.47亿元，同比增长2.34%。另一方面，去年，重药控股药品主业的停滞，靠器械增量填补。年报显示，重药控股2025年器械营收146.91亿元，同比增长15.24%，但毛利率从11.26%急跌至5.52%，下滑5.74个百分点。不仅如此，重药控股的高毛利品类对业绩提升有限。另一方面，重药控股的应收账款逐年增加，引发对其回款能力下滑的猜疑。应收账款增加的同时，重药控股坏账也在增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-05-18/doc-inhyiewm2897753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635707780","title":"重药控股（000950）披露2025年年度股东会决议公告，5月15日股价下跌1.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635707780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635707780?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:27","pubTimestamp":1778837277,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，重药控股报收于6.68元，较前一交易日下跌1.04%，最新总市值为115.44亿元。公告显示，公司于2026年5月14日召开2025年年度股东会，会议由董事会召集，采用现场与网络投票结合方式召开，出席股东代表股份占总表决权股份的59.4681%。会议审议通过了2025年度董事会工作报告、2025年年度报告、财务决算报告、2026年度财务预算报告及2025年度利润分配预案等全部议案，所有议案均获通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500031577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000950","BK0071","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634257725","title":"异动快报：重药控股（000950）5月12日10点12分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2634257725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634257725?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:21","pubTimestamp":1778552463,"startTime":"0","endTime":"0","summary":"证券之星5月12日盘中消息，10点12分重药控股（000950）触及涨停板。其所属行业医药商业目前下跌。领涨股为重药控股。该股为重庆国企改革，医疗耗材供应链SPD，国企改革概念热股，当日重庆国企改革概念上涨0.39%。5月11日的资金流向数据方面，主力资金净流入3452.12万元，占总成交额6.84%，游资资金净流出563.98万元，占总成交额1.12%，散户资金净流出2888.14万元，占总成交额5.72%。近5日资金流向一览见下表：重药控股主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200012086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000950","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633712762","title":"股市必读：重药控股（000950）5月7日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2633712762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633712762?lang=zh_cn&edition=full","pubTime":"2026-05-08 01:28","pubTimestamp":1778174892,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，重药控股报收于5.87元，上涨0.0%，换手率1.77%，成交量30.65万手，成交额1.8亿元。机构调研要点公司于2025年12月11日披露药友制药与上海复星医药产业发展有限公司及辉瑞签订许可协议，目前协议正常履行中。关于参股子公司与辉瑞合作的减肥药项目，公司将依规履行信息披露义务。公司公告汇总重药控股于2025年7月审议通过股份回购方案，拟使用8000万元至1亿元资金回购股份用于减资，价格不超过6.6元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800001515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0071","000950","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784808757071,"stockEarnings":[{"period":"1week","weight":-0.0483},{"period":"1month","weight":0.033},{"period":"3month","weight":-0.1185},{"period":"6month","weight":-0.1678},{"period":"1year","weight":0.0145},{"period":"ytd","weight":-0.0762}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0711},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.0651},{"period":"1year","weight":0.0796},{"period":"ytd","weight":-0.0257}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重药控股股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"52072人(较上一季度减少7.49%)","perCapita":"32892股","listingDate":"1999-09-16","address":"重庆市两江新区金石大道303号","registeredCapital":"171277万元","survey":" 重药控股股份有限公司的主营业务是医药商业、仓储物流、医药工业和研发等业务。公司的主要产品是药品、医疗器械、中药饮片、保健产品。","listedPrice":4.63},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"重药控股(000950)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供重药控股(000950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"重药控股,000950,重药控股股票,重药控股股票老虎,重药控股股票老虎国际,重药控股行情,重药控股股票行情,重药控股股价,重药控股股市,重药控股股票价格,重药控股股票交易,重药控股股票购买,重药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"重药控股(000950)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供重药控股(000950)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}